{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T21:40:42Z","timestamp":1782769242309,"version":"3.54.5"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Vancomycin is commonly utilized for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. Dosing recommendations for vancomycin have shifted in recent years to favor area under the concentration\u2013time curve (AUC) instead of trough-based dosing strategies to decrease vancomycin exposure and rates of acute kidney injury (AKI). However, little data exist on the safety and efficacy of AUC-based dosing in patients with obesity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a single-center retrospective cohort study conducted between 1 January 2014 and 31 December 2022. Adult patients aged \u226518 years were included if they were obese and received vancomycin for treatment of a severe MRSA infection for at least 72\u2005hours. The primary outcome was incidence of AKI based on Kidney Disease: Improving Global Outcomes (KDIGO) criteria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After initial screening, 398 patients were included, with 230 in the trough group and 168 in the AUC group. Rates of AKI were lower in the AUC group compared to the trough group (11.3% vs 25.2%, P &amp;lt; .001). After adjusting for potential confounders, logistic regression maintained a reduction in AKI with AUC-based dosing for cumulative doses less than the median of 10 250\u2005mg (odds ratio, 0.47 [95% confidence interval, .25\u2013.88]) but not for doses above. Rates of initial target attainment were also higher with AUC-based dosing (50.0% vs 23.9%, P &amp;lt; .001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients with obesity receiving vancomycin for treatment of severe MRSA infections experienced lower rates of AKI when utilizing an AUC- versus trough-based dosing strategy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaf205","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T13:49:13Z","timestamp":1743688153000},"source":"Crossref","is-referenced-by-count":2,"title":["Rates of Acute Kidney Injury Utilizing Area Under the Concentration\u2013Time Curve Versus Trough-Based Vancomycin Dosing Strategies in Patients With Obesity"],"prefix":"10.1093","volume":"12","author":[{"given":"Corey M","family":"Guidry","sequence":"first","affiliation":[{"name":"Department of Pharmacy: Clinical and Administrative Sciences, University of Oklahoma College of Pharmacy , Oklahoma City, Oklahoma ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily A","family":"Siegrist","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, OU Health , Oklahoma City, Oklahoma ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B","family":"Neely","sequence":"additional","affiliation":[{"name":"Department of Pharmacy: Clinical and Administrative Sciences, University of Oklahoma College of Pharmacy , Oklahoma City, Oklahoma ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndee","family":"Springer","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, United States Public Health Service Lawton Indian Hospital , Lawton, Oklahoma ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5657-7069","authenticated-orcid":false,"given":"Bryan P","family":"White","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, OU Health , Oklahoma City, Oklahoma ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"2025052712093219700_ofaf205-B1","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2025052712093219700_ofaf205-B2","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"2025052712093219700_ofaf205-B3","doi-asserted-by":"crossref","first-page":"e02042-17","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025052712093219700_ofaf205-B4","doi-asserted-by":"crossref","first-page":"20171122","DOI":"10.1128\/AAC.01293-17","article-title":"A quasi-experiment to study the impact of vancomycin area under the concentration-time curve\u2013guided dosing on vancomycin-associated nephrotoxicity","volume":"61","author":"Finch","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025052712093219700_ofaf205-B5","doi-asserted-by":"crossref","first-page":"e0088621","DOI":"10.1128\/AAC.00886-21","article-title":"Acute kidney injury associated with area under the curve versus trough monitoring of vancomycin in obese patients","volume":"66","author":"D\u2019Amico","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2025052712093219700_ofaf205-B6","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","article-title":"2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"149","author":"Martin","year":"2024","journal-title":"Circulation"},{"key":"2025052712093219700_ofaf205-B7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/phar.1531","article-title":"Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections","volume":"35","author":"Adane","year":"2015","journal-title":"Pharmacotherapy"},{"key":"2025052712093219700_ofaf205-B8","first-page":"2013","article-title":"Vancomycin volume of distribution estimation in adults with class III obesity","volume":"76","author":"Dunn","year":"2019","journal-title":"Am J Health Syst Pharm"},{"key":"2025052712093219700_ofaf205-B9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jiac.2015.03.007","article-title":"The association of elevated trough serum vancomycin concentrations with obesity","volume":"21","author":"Richardson","year":"2015","journal-title":"J Infect Chemother"},{"key":"2025052712093219700_ofaf205-B10","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1177\/1060028017720946","article-title":"Intravenous vancomycin associated with the development of nephrotoxicity in patients with class III obesity","volume":"51","author":"Choi","year":"2017","journal-title":"Ann Pharmacother"},{"key":"2025052712093219700_ofaf205-B11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/pharmacy11030095","article-title":"Evaluation of real-world vancomycin dosing and attainment of therapeutic drug monitoring targets","volume":"11","author":"Bradley","year":"2023","journal-title":"Pharmacy (Basel)"},{"key":"2025052712093219700_ofaf205-B12","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1177\/1060028019897100","article-title":"Comparison of vancomycin area-under-the-curve dosing versus trough target-based dosing in obese and nonobese patients with methicillin-resistant Staphylococcus aureus bacteremia","volume":"54","author":"Covvey","year":"2020","journal-title":"Ann Pharmacother"},{"key":"2025052712093219700_ofaf205-B13","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1177\/08971900221087122","article-title":"Which \u201cweigh\u201d to go? Alternative vancomycin dosing strategies in obese patients","volume":"36","author":"Wright","year":"2023","journal-title":"J Pharm Pract"},{"key":"2025052712093219700_ofaf205-B14","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1093\/jac\/dky310","article-title":"Dosing vancomycin in the super obese: less is more","volume":"73","author":"Crass","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2025052712093219700_ofaf205-B15","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1177\/00185787211055791","article-title":"Assessing nephrotoxicity associated with different vancomycin dosing modalities in obese patients at a community hospital","volume":"57","author":"Wolfe","year":"2022","journal-title":"Hosp Pharm"},{"key":"2025052712093219700_ofaf205-B16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.addr.2014.05.016","article-title":"Innovative approaches to optimizing the delivery of vancomycin in individual patients","volume":"77","author":"Pai","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"2025052712093219700_ofaf205-B17","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"2025052712093219700_ofaf205-B18","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/cc2872","article-title":"Acute renal failure\u2014definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) group","volume":"8","author":"Bellomo","year":"2004","journal-title":"Critical Care"},{"key":"2025052712093219700_ofaf205-B19","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"van Hal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2025052712093219700_ofaf205-B20","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1111\/bcp.15429","article-title":"Risk factors for vancomycin-associated acute kidney injury: a systematic review and meta-analysis","volume":"88","author":"Kim","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2025052712093219700_ofaf205-B21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ijantimicag.2017.08.012","article-title":"Dose, duration, and animal sex predict vancomycin-associated acute kidney injury in preclinical studies","volume":"51","author":"O\u2019Donnell","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2025052712093219700_ofaf205-B22","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1128\/AAC.01602-07","article-title":"Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2025052712093219700_ofaf205-B23","doi-asserted-by":"crossref","first-page":"5475","DOI":"10.1128\/AAC.00168-11","article-title":"Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial","volume":"55","author":"Bosso","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2025052712093219700_ofaf205-B24","doi-asserted-by":"crossref","first-page":"e02478-16","DOI":"10.1128\/AAC.02478-16","article-title":"Pilot study of a Bayesian approach to estimate vancomycin exposure in obese patients with limited pharmacokinetic sampling","volume":"61","author":"Carreno","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025052712093219700_ofaf205-B25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bcp.14144","article-title":"Population pharmacokinetics of vancomycin in obesity: finding the optimal dose for (morbidly) obese individuals","volume":"86","author":"Smit","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2025052712093219700_ofaf205-B26","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/FTD.0000000000000832","article-title":"Do vancomycin pharmacokinetics differ between obese and non-obese patients? Comparison of a general-purpose and four obesity-specific pharmacokinetic models","volume":"43","author":"Colin","year":"2021","journal-title":"Ther Drug Monit"},{"key":"2025052712093219700_ofaf205-B27","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/ajhp\/zxae262","article-title":"Pharmacists and vancomycin monitoring: a relationship timeline and lessons learned","volume":"82","author":"Jeffres","year":"2024","journal-title":"Am J Health Syst Pharm"},{"key":"2025052712093219700_ofaf205-B28","doi-asserted-by":"crossref","first-page":"ofac137","DOI":"10.1093\/ofid\/ofac137","article-title":"Approaching 65 years: is it time to consider retirement of vancomycin for treating methicillin-resistant Staphylococcus aureus endovascular infections?","volume":"9","author":"Rose","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025052712093219700_ofaf205-B29","doi-asserted-by":"crossref","first-page":"ofae217","DOI":"10.1093\/ofid\/ofae217","article-title":"Counting the cost of daptomycin versus vancomycin in hospitalized patients: a cost minimization analysis","volume":"11","author":"Wagner","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2025052712093219700_ofaf205-B30","doi-asserted-by":"crossref","first-page":"ofab659","DOI":"10.1093\/ofid\/ofab659","article-title":"Daptomycin-resistant Enterococcus bacteremia is associated with prior daptomycin use and increased mortality after liver transplantation","volume":"9","author":"Lee","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025052712093219700_ofaf205-B31","doi-asserted-by":"crossref","first-page":"ofy167","DOI":"10.1093\/ofid\/ofy167","article-title":"Clinical outcomes associated with linezolid resistance in leukemia patients with linezolid-resistant Staphylococcus epidermidis bacteremia","volume":"5","author":"Folan","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2025052712093219700_ofaf205-B32","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/jac\/dkq238","article-title":"Emergence of linezolid-resistant coagulase-negative Staphylococcus in a cancer centre linked to increased linezolid utilization","volume":"65","author":"Mulanovich","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2025052712093219700_ofaf205-B33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jare.2019.10.005","article-title":"Vancomycin resistant Staphylococcus aureus infections: a review of case updating and clinical features","volume":"21","author":"Cong","year":"2020","journal-title":"J Adv Res"},{"key":"2025052712093219700_ofaf205-B34","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1097\/CCM.0b013e318169167f","article-title":"Vasoactive drugs and acute kidney injury","volume":"36","author":"Bellomo","year":"2008","journal-title":"Crit Care Med"},{"key":"2025052712093219700_ofaf205-B35","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/10600280241273191","article-title":"The Acute Kidney Intervention and Pharmacotherapy (AKIP) list: standardized list of medications that are renally eliminated and nephrotoxic in the acutely ill","volume":"59","author":"Barreto","year":"2025","journal-title":"Ann Pharmacother"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf205\/62855186\/ofaf205.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/4\/ofaf205\/62855186\/ofaf205.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/4\/ofaf205\/62855186\/ofaf205.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:10:39Z","timestamp":1748362239000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf205\/8105439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,3,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf205","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,3,27]]},"article-number":"ofaf205"}}